<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172807</url>
  </required_header>
  <id_info>
    <org_study_id>205.226</org_study_id>
    <nct_id>NCT02172807</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Multiple Dose Comparison of 18 µg, 36 µg of Ba679BR (Tiotropium) Inhalation Capsules and Oxitropium Metered Dose Inhaler (2 Puffs of 100µg) in a 4-week, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the efficacy and safety of Ba679BR powder inhalation during the
      continuous once/day administration to the patients with COPD using oxitropium bromide
      (Tersigan® aerosol) as the comparator drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough forced expiratory volume in one second (FEV1.0) response</measure>
    <time_frame>Day 1, week 2 and 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1.0 response at 1 hour after administration</measure>
    <time_frame>Day 1, week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough forced vital capacity (FVC) response</measure>
    <time_frame>Day 1, week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC response at 1 hour after administration</measure>
    <time_frame>Day 1, week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow rate (PEF)</measure>
    <time_frame>in the morning and at evening every day until week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD symptom scores</measure>
    <time_frame>until week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of rescue use of β2 stimulant</measure>
    <time_frame>until week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's impression</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global evaluation</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG findings</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in laboratory values</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium low &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium 18 µg inhalation capsule and Placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium high &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium 36 µg inhalation capsule and Placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxitropium &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium low</intervention_name>
    <description>Tiotropium 18 µg inhalation capsule</description>
    <arm_group_label>Tiotropium low &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium high</intervention_name>
    <description>Tiotropium 36 µg inhalation capsule</description>
    <arm_group_label>Tiotropium high &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Placebo metered dose inhaler (MDI)</description>
    <arm_group_label>Tiotropium low &amp; Placebo</arm_group_label>
    <arm_group_label>Tiotropium high &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo inhalation capsule</intervention_name>
    <arm_group_label>Oxitropium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxitropium</intervention_name>
    <description>Oxitropium MDI (100 µg/puff)</description>
    <arm_group_label>Oxitropium &amp; Placebo</arm_group_label>
    <other_name>Tersigan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of COPD (chronic bronchitis, and emphysema) with stable symptoms:

          -  Screening FEV1.0 ≤70% of predicted normal vale and screening FEV1.0/FVC ≤70% (the
             baseline FEV1.0 should also be ≤70% of predicted normal value on the initial day of
             administration)

          -  Smoking history ≥ 10 pack-years (a peak-year is 20 cigarettes per day for one year or
             equivalent)

          -  Male or female patients 40 years of age or older

        Exclusion Criteria:

          -  History of bronchial asthma

          -  History of an atopic disease such as allergic rhinitis

          -  Total blood eosinophil count ≥ 600/µL

          -  Patient treated with antiallergic drugs or anti-histamine drugs

          -  Patients using oral corticosteroid medication at unstable doses (i.e. less than one
             month on a stable dose) or at a dose in excess of the equivalent of 10 mg of
             prednisolone per day

          -  Patients using inhaled steroid, oral β2 stimulant, theophylline preparation,
             expectorant or macrolide antibiotic at unstable doses (i.e. less than one month on a
             stable dose)

          -  Patients using an ACE inhibitor at unstable doses (i.e. less than one month on a
             stable dose)

          -  Patients with known narrow-angle glaucoma

          -  Patients with known symptomatic prostatic hypertrophy

          -  Patients with known hypersensitivity to anticholinergic drugs, lactose or any other
             components of the inhalation capsule delivery system

          -  Patients with significant diseases who in the opinion of the investigator were not
             eligible for the study

          -  Patients with clinically significant abnormal baseline laboratory test values
             (hematology, blood chemistry, urinalysis). Patients with serum glutamic-oxaloacetic
             transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) twice the upper
             limit of the normal range, bilirubin 150% or creatinine 125% of the upper limit of the
             normal range were excluded

          -  Patients with a recent history (i.e. within the 3 months prior to the screening visit)
             of myocardial infarction or heart failure

          -  Patients with any cardiac arrhythmia requiring drug therapy

          -  Patients who were treated with Patients who were treated with β-blockers-blockers

          -  Patients with regular use of daytime oxygen therapy

          -  Patients with known active tuberculosis or with obvious sequela of tuberculosis

          -  Patients with a history of cancer within the last 5 years. Patients with treated basal
             cell carcinoma were allowed

          -  Patients with a history of cystic fibrosis or bronchiectasis

          -  Patients with upper respiratory tract infection in the past one month prior to the
             screening visit or during the baseline period

          -  Patients who had taken an investigational drug within one month or six half lives
             (whichever is greater) prior to the screening visit

          -  Pregnant or nursing women or women of childbearing potential

          -  Other than the above, patients who in the opinion of the investigator were not
             eligible for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Oxitropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

